期刊
ANNALS OF HEMATOLOGY
卷 101, 期 1, 页码 11-19出版社
SPRINGER
DOI: 10.1007/s00277-021-04637-2
关键词
Secondary immune thrombocytopenia; Eltrombopag; Platelet response; Electronic health records; Retrospective study
类别
资金
- Novartis Pharmaceutical Corporation
The study found that in patients with secondary immune thrombocytopenia (sITP), the platelet response rate with eltrombopag was similar to that of primary ITP, and a treatment-free period was possible for a substantial minority of patients.
Immune thrombocytopenia (ITP) may occur in isolation (primary) or in association with a predisposing condition (secondary ITP [sITP]). Eltrombopag is a well-studied treatment for primary ITP, but evidence is scarce for sITP. We evaluated real-world use of eltrombopag for sITP using electronic health records. Eligible patients had diagnoses of ITP and a qualifying predisposing condition, and eltrombopag treatment. We described patient characteristics, treatment patterns, platelet counts, and thrombotic and bleeding events. We identified 242 eligible patients; the most common predisposing conditions were hepatitis C and systemic lupus erythematosus. Average duration of eltrombopag treatment was 6.1 months. Most (81.4%) patients achieved a platelet count >= 30,000/mu L at a mean of 0.70 months, 70.2% reached >= 50,000/mu L at a mean of 0.95 months, and 47.1% achieved a complete response of > 100,000/mu L at a mean of 1.43 months after eltrombopag initiation. At eltrombopag discontinuation, 105 patients (43%) experienced a treatment-free period for a mean 3.3 months. Bleeding events occurred with similar frequency before and during eltrombopag treatment whereas thrombotic events were less frequent during eltrombopag treatment. Our results suggest similar rates of platelet response with eltrombopag in patients with sITP as compared with primary ITP. In addition, a treatment-free period is possible for a substantial minority of patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据